Cybin Appoints Co-Founder Eric So as Interim CEO Following Drysdale's Departure
Cybin Inc. has appointed co-founder Eric So as interim CEO following Doug Drysdale's resignation, a leadership transition that comes as the company advances its late-stage psychedelic-based treatments for mental health disorders.
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) announced the resignation of Chief Executive Officer Doug Drysdale effective September 2, 2025, with co-founder and President Eric So assuming the role on an interim basis. The board of directors has established a committee to conduct a search for a new permanent CEO to lead the company through its commercialization phase.
This leadership transition is significant as Cybin operates as a late-stage neuropsychiatry company developing novel treatments for mental health conditions. The company's clinical pipeline includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder. CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to address substantial unmet medical needs.
Additionally, Cybin is advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 studies for generalized anxiety disorder. The company maintains a research pipeline of investigational compounds focused on 5-HT receptors, positioning itself at the forefront of psychedelic-based mental health treatments.
During this transition period, So will focus on advancing Cybin's clinical programs while ensuring operational continuity. The leadership change comes at a critical juncture as the company moves toward potential commercialization of its breakthrough therapies. Investors and stakeholders can access the latest company updates through its newsroom at https://ibn.fm/CYBN.
The appointment of a co-founder as interim CEO suggests the board values internal expertise and stability during this period of transition. Cybin's work in developing next-generation neuropsychiatry treatments addresses the substantial global unmet need for effective mental healthcare solutions. The company's operational presence spans Canada, the United States, the United Kingdom, and Ireland, reflecting its international scope and potential market reach.
This leadership development underscores the challenges and opportunities facing companies in the emerging psychedelic therapeutics sector as they navigate clinical development, regulatory pathways, and eventual commercialization strategies.